Evidence & policy library
Every pathway is linked to the organizations responsible for the decision.
11 source records
Methodology
Pathway information draws on official regulator, HTA and payer materials. Consult the cited policy for its conditions and effective date, and see Content & use for guidance on applying Atlas to your research.
Matching documents: 21
Market / scopeOfficial evidence recordTypePolicy / reference dateLast checked
APAC
🇹🇭 ThailandOfficialFacility and product registration, legally recognised applicant, GMP clearance and dossier formats.Current official frameworkLatest observed: Current official guidance
🇹🇭 ThailandOfficialProduct-specific registration information and the status of the shortage Priority Review guide; no universal review-time promise.Product-specific official guidanceLatest observed: Current registration and citizen-guide pages
🇹🇭 ThailandOfficialProduct-specific registration information and the status of the shortage Priority Review guide; no universal review-time promise.Product-specific official guidanceLatest observed: Current registration and citizen-guide pages
🇹🇭 ThailandOfficialDistinct conditional JA/CRP routes, national decisions, and facility versus product renewal. Product-specific renewal terms require the applicable instrument.JA 2024; CRP 2023-09-15Latest observed: Renewal parent includes 2026-07-16 and earlier notices
🇹🇭 Thailand
OfficialDistinct conditional JA/CRP routes, national decisions, and facility versus product renewal. Product-specific renewal terms require the applicable instrument.JA 2024; CRP 2023-09-15Latest observed: Renewal parent includes 2026-07-16 and earlier notices
🇹🇭 Thailand
OfficialDistinct conditional JA/CRP routes, national decisions, and facility versus product renewal. Product-specific renewal terms require the applicable instrument.JA 2024; CRP 2023-09-15Latest observed: Renewal parent includes 2026-07-16 and earlier notices
🇹🇭 Thailand
OfficialDistinct conditional JA/CRP routes, national decisions, and facility versus product renewal. Product-specific renewal terms require the applicable instrument.JA 2024; CRP 2023-09-15Latest observed: Renewal parent includes 2026-07-16 and earlier notices
🇹🇭 ThailandOfficialDistinct conditional JA/CRP routes, national decisions, and facility versus product renewal. Product-specific renewal terms require the applicable instrument.JA 2024; CRP 2023-09-15Latest observed: Renewal parent includes 2026-07-16 and earlier notices
🇹🇭 ThailandOfficial2021 assessment methods, discounting, threshold-price analysis and budget impact; not a newly issued 2026 threshold.2021 revision; publication 2023-05-19Latest observed: 2021 methods manual
🇹🇭 ThailandOfficialClinical and affordability criteria, generic-name listing and specific exceptions; no automatic rare/high-cost exemption.Current published selection criteriaLatest observed: Current official criteria page
🇹🇭 ThailandOfficialCall-specific proposal types, expert and Strategy review, conditional HTA/negotiation, fund affordability and advance transition communication.Current published processLatest observed: Current official process page
🇹🇭 ThailandOfficialCurrent categories, entry-specific commencement and adopted-versus-draft guidance. Scheme payment rules and exact patient conditions remain separate.Signed 2026-02-12; Gazette 2026-03-30Latest observed: Circulation page 2026-08-24; entry-specific commencement
🇹🇭 Thailand
OfficialCurrent categories, entry-specific commencement and adopted-versus-draft guidance. Scheme payment rules and exact patient conditions remain separate.Signed 2026-02-12; Gazette 2026-03-30Latest observed: Circulation page 2026-08-24; entry-specific commencement
🇹🇭 ThailandOfficialCurrent categories, entry-specific commencement and adopted-versus-draft guidance. Scheme payment rules and exact patient conditions remain separate.Signed 2026-02-12; Gazette 2026-03-30Latest observed: Circulation page 2026-08-24; entry-specific commencement
🇹🇭 ThailandOfficialCurrent categories, entry-specific commencement and adopted-versus-draft guidance. Scheme payment rules and exact patient conditions remain separate.Signed 2026-02-12; Gazette 2026-03-30Latest observed: Circulation page 2026-08-24; entry-specific commencement
🇹🇭 Thailand
OfficialSelected programme procurement, authorisation, GPO/company storage and VMI distribution; current item and scheme rules need separate confirmation.Publication date not explicit in the documentLatest observed: Official central-procurement mechanism reference
🇹🇭 ThailandOfficialA separate national reference-price process; not a current item price, universal purchasing ceiling or Thai FDA registration-price approval.Decision 2022-11-09; page 2023-04-17Latest observed: Published reference-price procedure
🇹🇭 Thailand
OfficialA separate national reference-price process; not a current item price, universal purchasing ceiling or Thai FDA registration-price approval.Decision 2022-11-09; page 2023-04-17Latest observed: Published reference-price procedure
🇹🇭 ThailandOfficialBroad regulatory and procurement context; underlying dates vary. The profile does not establish individual entitlements or a universal FDA-approved price.2025 profile; underlying reference years varyLatest observed: 2025 country profile
🇹🇭 ThailandOfficialScheme financing, provider payment and non-NLEM differences; current product-specific CGD, SSO and NHSO requirements remain separate.2024-05-28; source data years varyLatest observed: The Kingdom of Thailand health system review, second edition
🇹🇭 ThailandOfficialScheme financing, provider payment and non-NLEM differences; current product-specific CGD, SSO and NHSO requirements remain separate.2024-05-28; source data years varyLatest observed: The Kingdom of Thailand health system review, second edition
For education only — not regulatory, pricing or legal advice.